Home
>
National Drug Code (NDC)
>
LAMIVUDINE
LAMIVUDINE - 60505-3252-8 - (lamivudine)
Drug Information of LAMIVUDINE
| Product NDC: | 60505-3252 |
| Proprietary Name: | LAMIVUDINE |
| Non Proprietary Name: | lamivudine |
| Active Ingredient(s): | 300 mg/1 & nbsp; lamivudine |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, FILM COATED |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of LAMIVUDINE
| Product NDC: | 60505-3252 |
| Labeler Name: | Apotex Corp. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA091606 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20111202 |
Package Information of LAMIVUDINE
| Package NDC: | 60505-3252-8 |
| Package Description: | 1000 TABLET, FILM COATED in 1 BOTTLE (60505-3252-8) |
NDC Information of LAMIVUDINE
| NDC Code | 60505-3252-8 |
| Proprietary Name | LAMIVUDINE |
| Package Description | 1000 TABLET, FILM COATED in 1 BOTTLE (60505-3252-8) |
| Product NDC | 60505-3252 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | lamivudine |
| Dosage Form Name | TABLET, FILM COATED |
| Route Name | ORAL |
| Start Marketing Date | 20111202 |
| Marketing Category Name | ANDA |
| Labeler Name | Apotex Corp. |
| Substance Name | LAMIVUDINE |
| Strength Number | 300 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
